Apolipoprotein E (apoE)-deficient mice develop marked hyperlipidemia as well as atherosclerosis and thus are an excellent animal model for evaluating the potential for gene therapy in human genetic dyslipoproteinemias. Recombinant adenovirus containing either human apoE (rAdv.apoE) or the reporter gene luciferase (rAdv.luc) were generated and infused intravenously in apoE-deficient mice with preinfusion plasma total cholesterol of 644 +/-149 mg/dl an cholesterol rich VLDL/IDL. After a single infusion of rAdv.apoE, plasma concentrations of human apoE ranging from 1.5 to 650 mg/dl were achieved. Adenovirusmediated apoE replacement resulted in normalization of the lipid and lipoprotein profile with markedly decreased total cholesterol (103 +/-18mg/dl), VLDL, IDL, and LDL, as well as increased HDL. Measurement of aortic atherosclerosis 1 mo after adenoviral infusion demonstrated a marked reduction in the mean lesion area of mice infused with rAdv.apoE (58 +/-8 x 10(3) microns2) when compared with control mice infused with rAdv.luc (161 +/-10 x 10(3) microns2; P < 0.0001). Thus, apoE expression for 4 wk was sufficient to markedly reduce atherosclerosis, demonstrating the feasibility of gene therapy for correction of genetic hyperlipidemias resulting in atherosclerosis. The combined use of adenovirus vectors and the apoE-deficient mouse represents a new in vivo approach that will permit rapid screening of candidate genes for the prevention of atherosclerosis.
Introduction
Apolipoprotein E (apoE), a 36-kD plasma glycoapolipoprotein, plays a key role in lipoprotein metabolism by facilitating the cellular uptake of remnants of triglyceride-rich chylomicrons and VLDL (for review see references 1 and 2). Human apoE is polymorphic and consists of three major isoproteins of which apoE-3 is the most common. In lipoprotein metabolism, apoE serves as a ligand on lipoprotein particles for the LDL receptor and has also been proposed as a ligand for LDL receptor-related protein, the putative remnant receptor, as well as the VLDL receptor (3) (4) (5) (6) (7) (8) . The important role that apoE plays in facilitating lipoprotein transport has been established in part by the identification of patients with apoE deficiency (9) (10) (11) (12) (13) or, more commonly, patients with a structural defect in apoE that results in decreased affinity for the lipoprotein receptors (14) (15) (16) (17) . A defect in the function of apoE leads to delayed plasma clearance of remnants of triglyceride-rich lipoproteins and the development of dysbetalipoproteinemia or type HI hyperlipoproteinemia. The majority of patients with type Ill hyperlipoproteinemia have the apoE-2 isoform which has reduced binding to the lipoprotein receptors. Type Ill hyperlipoproteinemia is characterized by elevated plasma levels of cholesterol, triglycerides, atherogenic cholesterol rich remnants of chylomicrons, and VLDL, as well as by the presence of xanthomas and development of premature cardiovascular disease.
A mouse model for apoE deficiency has been developed using homologous recombination with apoE-targeted gene disruption in embryonic stem cells (18) . The apoE-deficient mice develop marked hypercholesterolemia with total cholesterol levels five-to six-fold greater than control mice (19, 20) . These apoE-deficient mice have a dramatic shift in plasma lipoproteins from HDL, the major lipoprotein in control mice, to cholesterolenriched remnants of chylomicrons and VLDL. Of particular interest in the apoE-deficient mice is the development of spontaneous atherosclerosis on a normal chow diet (20) (21) (22) . The apoE-deficient mouse represents a unique model to study gene replacement of a plasma apolipoprotein for correction of a genetic dyslipoproteinemia. The correction of the apoE deficiency in this animal model presents several interesting challenges. For apoE to function in facilitating the clearance of lipoprotein remnants, gene replacement must be followed by synthesis and secretion of the apolipoprotein in a pathway that will permit it to become associated with both hepatic proteoglycans and plasma lipoproteins. In addition, to achieve replacement of apoE at levels observed in normal control animals, it must be expressed in the milligrams per deciliter level in plasma, that has not been readily achieved in previous gene replacement studies. A recent study indicates that bone marrow transplantation with replacement of apoE by using apoE-expressing myeloid cells in apoEdeficient mice may correct the metabolic defect as well the dietenhanced atherosclerosis in these animals (23) . In humans and normal mice, however, the major site of synthesis of apoE appears to be the liver (2, 24) .
In this report, we describe the successful correction of apoE deficiency in apoE-deficient mice by using an alternative approach involving systemic delivery to mouse liver of recombi- (Fig. 1) .
Human apoE in mouse plasma was quantitated by a sandwich ELISA using microtiter immunoassay plates (Immulon 1; Dynatech Laboratories, Chantilly, VA) coated with a monoclonal apoE antibody ABE2 (University of Ottawa Heart Institute, Ottawa, Ontario, Canada) for capture. Purified mouse apoE and recombinant human apoE3 were quantitated by amino acid analysis. Purified recombinant human apoE3 in progressive dilutions in apoE-deficient human plasma was used to generate a standard curve from 0 to 200 ng/ml. A polyclonal rabbit apoE antibody followed by a goat anti-rabbit peroxidase-conjugated antibody was used for detection. The within-run coefficient of variation of the apoE assays was 12%. Mouse apoE quantitation was performed by computerized densitometry of apoE immunoreactive bands on protein immunoblots as described below. Purified mouse apoE was used to generate a standard curve on each gel from 5 to 40 ng and a polyclonal apoE antibody (Biodesign International, Kennebunkport, ME) was used for detection.
Immunoblotting was performed on a 10% Tris glycine gel (Novex, San Diego, CA) using standard Laemmli buffer containing SDS and mercaptoethanol. The samples (1 pIl of plasma diluted 10-fold with Evaluation of atherosclerosis. The heart and attached section of ascending aorta were dissected en bloc and placed in 0.9% saline for 1 h followed by fixing in 4% formaldehyde for 24 h and then 10% formaldehyde for 5 d as described previously (37) . The specimens were embedded in 25% gelatin and then sectioned using a cryostat at -250C.
The aortic root and ascending aorta were sectioned at a thickness of 10 ,um and alternate sections were saved on slides and stained with Oilred-O for neutral lipids and hematoxylin for nucleic tissue. Five sections per animal were evaluated for the cross-sectional area of lesions from the aortic root for a distance of -350 jim at 80 ,m intervals (37, 38) .
The groups were statistically analyzed using unpaired Student's t test.
Results
The plasma lipids and lipoproteins present in the apoE-deficient and control C57black mice are summarized in Table I Fig. 1, A and B . In control mice (Fig. 1 A) , the lipoprotein profile revealed HDL as the predominant lipoprotein with only small amounts of VLDL and LDL. In contrast, the major lipoproteins in the apoE-deficient mice (Fig. 1 B) were VLDL and IDL with a significant reduction in HDL. The combined lipids and lipoprotein profiles in the apoE-deficient mice are consistent with delayed clearance of triglyceride-rich lipoproteins leading to markedly elevated cholesterol-enriched remnant lipoproteins.
To determine the efficacy of apoE gene replacement, apoEdeficient mice were infused intravenously with a recombinant adenovirus containing the apoE gene designated rAdv.apoE driven by a CMV promoter and enhancer. A similar recombinant adenovirus containing the luciferase gene (rAdv.luc) was used as a control for viral-induced changes in plasma lipoproteins. The recombinant luciferase adenovirus construct was also used for the determination of the tissue distribution of the adenoviral-mediated gene delivery because of the availability of a sensitive quantitative assay (39) . The tissue distribution of transgene expression after intravenous rAdv.luc infusion is summarized in Fig. 2 . Consistent with previous reports (40 -42) which have demonstrated expression of the transgene in virtually all the hepatocytes examined, the liver was the major organ ApoE deficient rAdv.luc rAdv.apoE controls Figure 5 . Aortic atherosclerosis after adenoviral infusion. 10 Infusion of apoE-deficient mice with either 2 x 108 or 3 x 109 pfu of rAdv.apoE resulted in low and high levels of expression of plasma apoE, respectively. At 4 d after injection, the plasma apoE levels ranged in the low expressors from 1.5 to 35 mg/dl (mean = 11.3 mg/dl, n = 7) to 536-648 mg/dl in the high expressor animals (Table II) . Further evidence of apoE production was obtained by immunoblot analysis of mouse plasma (Fig. 3) . Analysis of plasma from the apoEdeficient mice starting at day 4 after injection with rAdv.apoE revealed the 36-kD E apolipoprotein band which could be detected in decreasing intensity for up to 34 d. Marked overexpression of apoE in the high expressor animal group was transient, with levels of apoE decreasing to the range of the low expressor group by 8-12 d.
The plasma lipids and lipoproteins of the apoE-deficient mice injected with rAdv.apoE as compared with apoE-deficient animals injected with rAdv.luc and control mice are summarized in Table III . 4 sufficient to achieve a physiological correction of the lipid abnormalities. No significant change in the lipoprotein profile was observed when the apoE-deficient mice were injected with rAdv.luc, indicating that injection of an adenovirus with an irrelevant transgene had no effect on the plasma lipids and lipoproteins in the apoE-deficient mice.
The FPLC profiles of the plasma lipoproteins of the apoEdeficient mice at day 4 after rAdv.apoE infusions are shown in Fig. 1, C and D . The marked elevation of the cholesterol-rich VLDL and IDL in the apoE-deficient mice after rAdv.apoE injection was normalized to a profile that was similar to control mice with HDL as the major plasma lipoprotein. Immunoblot analysis of the individual fractions across the FPLC elution profile revealed the presence of apoE primarily in the apoA-I containing HDL FPLC fractions, indicating that apoE had been incorporated into the mouse plasma lipoproteins (Fig. 3, right  lanes) .
The duration of changes in the plasma lipids after rAdv.apoE infusion is illustrated in Fig. 4 . The apoE-deficient mice receiving rAdv.apoE had a rapid decrease in total cholesterol by day 2 with a maximum correction at day 4 and then a gradual return toward baseline. By day 30, the plasma cholesterol levels were still approximately half those of the untreated apoE-deficient mice. A reduction in plasma cholesterol persisted in the rAdv.apoE-injected mice for up to 60 d, thus establishing the ability of the transgene to synthesize and secrete apoE in sufficient levels to modulate lipoprotein metabolism. The animals with transient marked overexpression of apoE had similar cholesterol reduction (total cholesterol = 161 mg/dl on day 8) and expression as the low expressor group with plasma cholesterol returning toward baseline by day 46.
To determine the effect of apoE gene replacement on spontaneous atherosclerosis, apoE-deficient mice were killed, and aortic atherosclerotic lesion areas were examined and quantitated histologically. Previous analyses of atherosclerotic lesion development in apoE-deficient mice in our laboratory demonstrated initial aortic lesions forming at 3 mo of age with rapid progression to complex atherosclerotic lesions by 5 mo of age (data not shown) consistent with animals analyzed in previously reported studies (20, 21). Therefore, 4-mo-old male animals with aortic atherosclerotic lesion area of -30 X 103 um2 were chosen for the study and remained on a normal chow diet (4.5% fat, 0% cholesterol) during the study. apoE-deficient mice had a mean lesion area per section of 136±18 X 103 ILm2 (±SEM; n = 15 sections from three animals) at 5 mo of age (Fig. 5) . As previously described (20, 21), these animals had characteristic atherosclerotic lesions that started in the aortic sinus and ex- Figure 6 . Proximal aortic sections from apoE-deficient mice. All sections were stained with Oil-red-O and hematoxylin and then counterstained with light green. Sections from an apoE-deficient mouse at 5 mo of age are on the left; sections from an apoE-deficient mouse at 5 mo of age after receiving rAdv.apoE 1 mo before on the right. The apoE-deficient animal has significant atherosclerotic changes with marked lipid accumulation and fibrosis (A and B). An animal of the same age after rAdv.apoE treatment has an absence of complex lesion development with minimal lipid staining of the intima (C and D). A and C, x30; B and D, x75. tended distally along the ascending aorta in all sections examined. The raised lesions had marked red staining areas using Oil-red-O indicating lipid accumulation with lipid-laden macrophages, extracellular lipid deposits, necrosis, and fibrosis (Fig.  6, A and B) . Another subset of 4-mo-old apoE-deficient mice was infused with either rAdv.luc or rAdv.apoE and then killed 4 wk later at 5 mo of age. The rAdv.luc-infused mice had a mean lesion area per section of 161±19 X 103 ,im2 (n = 15 sections from three animals) and had lesions similar to control apoE-deficient mice. However, apoE-deficient animals expressing apoE had mean aortic lesion areas that were significantly smaller (58±8 x 103 1um2; n = 20 sections from four animals; P < 0.0001) than the animals infused with rAdv.luc (Fig. 5) . The aortas from the apoE-treated mice showed minimal lipid staining and an absence of complex lesion formation (Fig. 6 (1) .
In this study, we have selected the apoE-deficient mouse to determine the feasibility of apolipoprotein gene replacement in the genetic dyslipoproteinemias. To achieve an effective correction of the gene defect in the apoE-deficient animals, the apoE transgene must be expressed, apoE must be secreted from the liver, and the protein must associate with hepatic proteoglycans as well as plasma lipoproteins. The role of apoE in lipoprotein remnant clearance is to serve as a ligand on hepatic proteoglycans for the initial interaction of the lipoprotein particle with the cell after which there is an apoE-mediated specific interaction with the membrane lipoprotein receptors (3) (4) (5) (6) (7) (8) . As reviewed above, the apoE transgene must be expressed in the milligrams per deciliter range to achieve plasma levels similar to those present in humans and normal mice. Previous studies have demonstrated that intravenous delivery of recombinant adenovirus results in the expression of apoA-I (42) and Factor IX (40) in normal mice as well as successful correction of the metabolic defects associated with ornithine transcarbamylase (43) and LDL-receptor deficiency (41) in two mouse models for these genetic disorders. However, milligrams/deciliter levels of transgene expression associated with complete correction of a genetic disease have not been consistently achieved in most in vivo adenoviral gene therapy studies in mice (40-44). One of the major limitations of the currently used adenovirus vector system is the short-term expression of the transgene (40, 41, [45] [46] [47] [48] which in most cases is limited to less than 2 mo. Recent data suggest that this limited expression is due at least in part to the development of an immune response directed against viral late gene proteins that continue to be expressed with the current generation of adenovirus vectors (43, 49) . Interestingly, despite the ability of the adenovirus vectors to transduce a wide variety of cells (28, 43, (50) (51) (52) (53) (54) (55) , intravenous infusion appears to preferentially target the liver, the major site of synthesis of plasma lipoproteins and apoE (40, 42, 43) . Thus, we used recombinant adenovirus to evaluate the feasibility of correcting the marked hyperlipidemia and atherosclerosis in apoE-deficient mice after transient delivery of the human apoE gene to the liver.
Using the replication-deficient adenovirus vector system, we have achieved complete correction of the hypercholesterolemic lipoprotein profile in the apoE-deficient mouse. Plasma cholesterol levels were reduced from the 650 mg/dl range to the 100-150 mg/dl levels of control mice. apoE could be detected in plasma by immunoblot analysis and by ELISA, and both low as well as high plasma levels of apoE associated primarily with mouse HDL were achieved. Interestingly, near the completion of our studies, Stevenson et al. reported (56) the lipoprotein profile observed after adenovirus-mediated gene transfer in apoE-deficient mice and indicated that the majority of expressed apoE associated with VLDL. However, in their study, an adenoviral construct with a Rous sarcoma virus (RSV) promoter was used resulting in apoE expression in the range of 0.12 mg/ dl. This level of apoE expression did not result in complete normalization of the elevated plasma VLDL when analyzed by FPLC, and the expressed apoE was associated with the cholesterol-rich VLDL. In contrast, in our report, FPLC analysis of the plasma lipoproteins of the apoE-deficient mice after rAdv.apoE infusion revealed a virtual complete shift from the cholesterolrich VLDL and IDL to HDL, the predominant lipoprotein characteristic of normal mice. The expressed apoE was associated primarily with HDL in our studies. Expression of the transgene was detected up to 1 mo after adenoviral injection and was accompanied by persistent cholesterol reduction.
Since most strains of mice are resistant to atherosclerosis, atherogenic diets to induce the development of atherosclerotic lesions have been needed in previous studies (38, 57) . However, in the apoE-deficient animal, lesions form even when the animals are fed a normal chow diet. The effect of correction of the apoE gene defect on the development of this spontaneous atherosclerosis in the apoE-deficient mouse was determined in apoE-deficient mice 4 wk after rAdv.apoE infusion. The expression of apoE and correction of the hyperlipidemia for up to 4 wk after apoE gene replacement were sufficient enough to significantly reduce atherosclerosis in apoE-deficient mice. These animals demonstrated a significant decrease in the mean lesion area in the aortas when compared with control apoEdeficient mice infused with rAdv.luc or left untreated. Comparison of lesion area in 4-mo-old apoE-deficient mice and the rAdv.apoE-treated apoE-deficient animals suggests that the significant reduction in atherosclerosis in the latter group primarily reflects the prevention of progressive lesion formation rather than regression. This is consistent with the observation that, compared with the control groups, the rAdv.apoE-infused apoEdeficient animals had lesions with minimal lipid staining of the intima and no evidence of prior fibrosis. Presently, no practical noninvasive method exists to assess the baseline atherosclerosis before adenoviral infusion in each individual animal to definitively document regression of atherosclerotic lesions. However, older animals with more advanced lesions may be useful in subsequent studies to assess regression of atherosclerosis with transient apoE expression. Of major importance, however, is the finding that adenovirus-mediated transient expression of apoE resulted in modification of a major, complex clinical end point, atherosclerosis, in adult apoE-deficient mice.
These combined results provide definitive evidence that marked hyperlipidemia and atherosclerosis resulting from a molecular defect in a plasma apolipoprotein can be effectively corrected by adenovirus-mediated gene therapy. Based on these studies, we propose that the combined use of adenovirus vectors and the apoE-deficient mouse may provide a new and novel approach for the rapid screening of candidate genes for prevention of atherosclerosis.
